Eli Lilly Quarterly Cash Flow Statement
NYSE: LLYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 1,179.80 +0.04%
Eli Lilly free cash flow
In the quarter ended Jun 30, 2026, Eli Lilly generated $10.69 billion of operating cash flow and spent $2.93 billion on capital expenditures. That left free cash flow of $7.76 billion, a free-cash-flow margin of 33.8% of revenue. Free cash flow was up 458.1% from the prior year's $1.39 billion.
Eli Lilly returned $3.15 billion to shareholders: $1.55 billion in dividends and $1.60 billion in share repurchases, equal to 41% of free cash flow. Free cash flow covered dividend payments 5.0 times.
Summary generated from market data by MetaCap's automated system. Methodology
Eli Lilly cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 7.09B | 7.40B | 6.64B | 5.58B | 5.66B | 2.76B | 4.41B | 970.30M | 2.97B | 2.24B | 2.19B | -57.40M |
| Net Income growth (YoY) | +25.33% | +168.07% | +50.52% | +475.34% | +90.80% | +23.01% | +101.43% | — | +68.27% | +66.77% | +12.98% | -103.95% |
| Depreciation & Amortization | 534.00M | 509.00M | 585.70M | 470.30M | 478.00M | 463.00M | 485.20M | 466.80M | 414.40M | 400.60M | 387.40M | 411.00M |
| Stock-Based Compensation | 201.00M | 161.00M | 136.10M | 150.90M | 185.00M | 154.00M | 142.30M | 133.20M | 211.10M | 159.40M | 120.70M | 215.60M |
| Operating Cash Flow | 10.69B | 5.33B | 3.22B | 8.84B | 3.09B | 1.67B | 2.47B | 3.71B | 1.47B | 1.17B | -312.00M | 2.19B |
| Capital Expenditures | -2.93B | -2.33B | -2.55B | -2.09B | -1.70B | -1.51B | -1.50B | -1.35B | -1.22B | -986.30M | -1.07B | -970.30M |
| Investing Cash Flow | -15.40B | -3.92B | -2.80B | -2.98B | -1.83B | -3.35B | -1.92B | -4.00B | -2.20B | -1.18B | -2.92B | -3.08B |
| Dividends Paid | -1.55B | -1.55B | -1.35B | -1.35B | -1.35B | -1.35B | -1.17B | -1.17B | -1.17B | -1.17B | -1.02B | -1.02B |
| Share Repurchases | -1.60B | -2.36B | -1.51B | -708.30M | -692.00M | -1.20B | -2.05B | -446.10M | 0 | 0 | 0 | 0 |
| Debt Issued | 8.94B | 0 | -200.00K | 6.71B | 0 | 6.46B | -100.00K | 4.96B | 0 | 6.45B | 500.00K | 0 |
| Debt Repaid | -873.00M | -750.00M | 100.00K | -100.00K | -778.00M | 0 | 200.00K | 0 | — | — | 0 | 0 |
| Financing Cash Flow | 8.43B | -3.47B | -2.88B | 530.80M | -1.25B | 1.38B | -225.50M | 211.30M | 1.56B | -311.30M | 3.55B | 572.00M |
| Net Change in Cash | 3.67B | -1.99B | -2.52B | 6.42B | 283.00M | -175.00M | -101.40M | 145.40M | 763.40M | -358.40M | 438.20M | -313.70M |
| Free Cash Flow | 7.76B | 3.01B | 677.90M | 6.75B | 1.39B | 156.00M | 977.70M | 2.36B | 241.40M | 179.70M | -1.38B | 1.22B |
This table shows 12 quarterly periods of Eli Lilly's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow LLY's reporting calendar. What is a cash flow statement?